Takeda Pharmaceutical Stock Forecast, Price & News

Takeda Pharmaceutical (NYSE:TAK) Frequently Asked Questions

Is Takeda Pharmaceutical a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Takeda Pharmaceutical in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Takeda Pharmaceutical stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TAK, but not buy additional shares or sell existing shares.
View analyst ratings for Takeda Pharmaceutical or view top-rated stocks.

How has Takeda Pharmaceutical's stock price been impacted by Coronavirus (COVID-19)?

Takeda Pharmaceutical's stock was trading at $17.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TAK stock has decreased by 20.3% and is now trading at $13.66.
View which stocks have been most impacted by COVID-19.

When is Takeda Pharmaceutical's next earnings date?

Takeda Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Takeda Pharmaceutical.

How were Takeda Pharmaceutical's earnings last quarter?

Takeda Pharmaceutical Company Limited (NYSE:TAK) released its earnings results on Thursday, October, 28th. The company reported $0.45 earnings per share for the quarter. The company had revenue of $7.67 billion for the quarter. Takeda Pharmaceutical had a net margin of 15.78% and a trailing twelve-month return on equity of 12.66%.
View Takeda Pharmaceutical's earnings history.

Is Takeda Pharmaceutical a good dividend stock?

Takeda Pharmaceutical pays an annual dividend of $0.34 per share and currently has a dividend yield of 2.54%. The dividend payout ratio of Takeda Pharmaceutical is 21.52%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Takeda Pharmaceutical will have a dividend payout ratio of 36.56% next year. This indicates that Takeda Pharmaceutical will be able to sustain or increase its dividend.

What guidance has Takeda Pharmaceutical issued on next quarter's earnings?

Takeda Pharmaceutical updated its FY 2021 earnings guidance on Thursday, November, 4th. The company provided earnings per share (EPS) guidance of $3.530-$3.530 for the period. The company issued revenue guidance of $30.22 billion-$30.22 billion.

Who are Takeda Pharmaceutical's key executives?

Takeda Pharmaceutical's management team includes the following people:

• Christophe Weber, President, CEO & Representative Director
• Constantine Saroukos, Chief Financial Officer & Director
• Andrew S. Plump, Director, Research & Development President
• Michael E. Mendelsohn, Chief Medical & Scientific Officer
• Norimasa Takeda, Chief Accounting Officer & Corporate Controller

Who are some of Takeda Pharmaceutical's key competitors?

Some companies that are related to Takeda Pharmaceutical include AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Zoetis (ZTS), CSL (CSLLY), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Bayer Aktiengesellschaft (BAYRY), MERCK Kommanditgesellschaft auf Aktien (MKGAF), Astellas Pharma (ALPMY), BeiGene (BGNE), Genmab A/S (GNMSF), Genmab A/S (GMAB) and Royalty Pharma (RPRX).
View all of TAK's competitors.

What other stocks do shareholders of Takeda Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Takeda Pharmaceutical investors own include Cisco Systems (CSCO), Johnson & Johnson (JNJ), Alibaba Group (BABA), Pfizer (PFE), Verizon Communications (VZ), AbbVie (ABBV), CVS Health (CVS), Gilead Sciences (GILD), AT&T (T) and Abbott Laboratories (ABT).

What is Takeda Pharmaceutical's stock symbol?

Takeda Pharmaceutical trades on the New York Stock Exchange (NYSE) under the ticker symbol "TAK."

Who are Takeda Pharmaceutical's major shareholders?

Takeda Pharmaceutical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Glenview Capital Management LLC (0.26%), Macquarie Group Ltd. (0.15%), Goldman Sachs Group Inc. (0.08%), Renaissance Technologies LLC (0.07%), Morgan Stanley (0.06%) and BlackRock Inc. (0.06%).

Which major investors are selling Takeda Pharmaceutical stock?

TAK stock was sold by a variety of institutional investors in the last quarter, including Glenview Capital Management LLC, GMT Capital Corp, CIBC Asset Management Inc, Millennium Management LLC, Franklin Resources Inc., Renaissance Technologies LLC, Comerica Bank, and Janus Henderson Group PLC.

Which major investors are buying Takeda Pharmaceutical stock?

TAK stock was purchased by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Barclays PLC, Van ECK Associates Corp, EP Wealth Advisors LLC, Russell Investments Group Ltd., BlackRock Inc., Summit Global Investments, and FNY Investment Advisers LLC.

How do I buy shares of Takeda Pharmaceutical?

Shares of TAK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Takeda Pharmaceutical's stock price today?

One share of TAK stock can currently be purchased for approximately $13.66.

How much money does Takeda Pharmaceutical make?

Takeda Pharmaceutical has a market capitalization of $43.23 billion and generates $30.17 billion in revenue each year. The company earns $3.53 billion in net income (profit) each year or $1.58 on an earnings per share basis.

How many employees does Takeda Pharmaceutical have?

Takeda Pharmaceutical employs 47,000 workers across the globe.

Does Takeda Pharmaceutical have any subsidiaries?

The following companies are subsidiares of Takeda Pharmaceutical: ARIAD Pharmaceuticals, Baxalta Manufacturing S.à r.l., IDM Pharma Inc., Intellikine, Inviragen, LigoCyte Pharmaceuticals, Meritage Pharma Inc., Millennium Pharmaceuticals, Millennium Pharmaceuticals Inc., Nihon Pharmaceutical Co. Ltd., Nycomed Pharma, PvP Biologics, Shire, Shire ViroPharma LLC, Takeda (China) Holdings Co. Ltd., Takeda AS, Takeda Austria GmbH, Takeda Bio Development Center, Takeda California Inc., Takeda Consumer Healthcare Company Limited, Takeda Development Center Americas Inc., Takeda Development Center Asia Pte. Ltd., Takeda Development Centre Europe Ltd., Takeda Distribuidora Ltda., Takeda France S.A.S., Takeda GmbH, Takeda Ireland Limited, Takeda Italia S.p.A., Takeda Pharma A/S, Takeda Pharmaceutical (China) Company Limited, Takeda Pharmaceuticals International AG, Takeda Pharmaceuticals Korea Co. Ltd., Takeda Pharmaceuticals Limited Liability Company, Takeda Pharmaceuticals U.S.A. Inc., Takeda UK Limited, Takeda Vaccines Inc., Takeda Vaccines Pte. Ltd., and TiGenix.

When was Takeda Pharmaceutical founded?

Takeda Pharmaceutical was founded in 1781.

What is Takeda Pharmaceutical's official website?

The official website for Takeda Pharmaceutical is www.takeda.com.

Where are Takeda Pharmaceutical's headquarters?

Takeda Pharmaceutical is headquartered at 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668.

How can I contact Takeda Pharmaceutical?

Takeda Pharmaceutical's mailing address is 1-1 NIHONBASHI-HONCHO 2-CHOME CHUO-KU, TOKYO M0, 103-8668. The company can be reached via phone at (166) 204-2111 or via fax at 813-3278-2268.